FDA Accepts BLA for Merck’s Monoclonal Antibody for Infant Protection Against RSV
December 17th 2024The PDUFA date is set for early June, and if approved, it would be the first and only single dose immunization for infants regardless of weight designed to protect them for the duration of their first RSV season.
Hepatitis C and Homelessness: Assessing Risk Factors
December 9th 2024Focused prevention policies and support systems have shown to reduce HCV prevalence in at-risk groups. Addressing factors like IDU, lack of income, and alcohol misuse through targeted education and interventions is essential to mitigate HCV infection rates locally and globally.
Early-Stage Antibiotic for Bone and Joint Infections Comparable to Standard of Care Therapy
December 9th 2024A small phase 2 study evaluated Debiopharm’s investigational antibiotic, afabicin, including its clinical response rate and safety profile of 2-3 weeks of treatment for staphylococcal bone and joint infections (BJI).
Top 5 Infectious Disease News Stories Week of November 30-December 6
December 7th 2024This week, a Mayo Clinic study found that removing C diff from gastrointestinal pathogen panels reduced unnecessary treatments, a Salmonella outbreak was linked to cucumbers, and a hepatitis C therapy achieved a 98% sustained virologic response in non-cirrhotic patients, among other developments.